Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms JNJ 70218902 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), TMEFF2 inhibitors(Tomoregulin-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 10 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | IL | 10 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | ES | 10 Jul 2020 |
NCT04397276 (ESMO2022) Manual | Phase 1 | 73 | kfkeiftojp(aloabzobwe) = jncoswctxx exgyhrrbax (ufhfjqtkah ) View more | Positive | 10 Sep 2022 |